Eytan M. Stein

Eytan M. Stein, MD, is an Assistant Professor on the Leukemia Service at Memorial Sloan Kettering Cancer Center. He has a particular interest in Acute Myeloid Leukemia (AML) and conducts novel, phase I clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies. Dr. Stein led the clinical study of the IDH2 inhibitor Enasidenib in patients with relapsed and refractory AML that led to its FDA approval in August 2017. He also leads a variety of phase 1 clinical trials with antibody drug conjugates, bromodomain inhibitors, MDM2 inhibitors, DHODH inhibitors and is a clinical investigator on the BEAT AML master clinical trial. His current research focuses on elucidating mechanisms of resistance to IDH inhibitors and developing clinical trials that combine epigenetic and targeted therapy for the treatment of AML.